• 1

    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277300.

  • 2

    Karumanchi SA, Merchan J, Sukhatme VP. Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens 2002;11:3742.

    • Search Google Scholar
    • Export Citation
  • 3

    Choyke PL, Glenn GM, Walther MM. Hereditary renal cancers. Radiology 2003;226:3346.

  • 4

    DeVita VT Jr, Hellman S, Rosenberg SA. Cancer Principles and Practice of Oncology. 8th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.

    • Search Google Scholar
    • Export Citation
  • 5

    Horner MJ, Ries LA, Krapcho M. SEER Cancer Statistics Review, 1975-2006. National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2006/. Accessed June 21, 2011.

    • Search Google Scholar
    • Export Citation
  • 6

    Hricak H, Demas BE, Williams RD. Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. Radiology 1985;154:709715.

    • Search Google Scholar
    • Export Citation
  • 7

    Janus CL, Mendelson DS. Comparison of MRI and CT for study of renal and perirenal masses. Crit Rev Diagn Imaging 1991;32:69118.

  • 8

    Blom JH, van Poppel H, Marechal JM. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 2009;55:2834.

    • Search Google Scholar
    • Export Citation
  • 9

    Blute ML, Leibovich BC, Cheville JC. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. J Urol 2004;172:465469.

    • Search Google Scholar
    • Export Citation
  • 10

    Kuczyk M, Munch T, Machtens S. The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover experience. BJU Int 2002;89:517522.

    • Search Google Scholar
    • Export Citation
  • 11

    Kuczyk M, Wegener G, Jonas U. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. Eur Urol 2005;48:252257.

    • Search Google Scholar
    • Export Citation
  • 12

    O’Malley RL, Godoy G, Kanofsky JA, Taneja SS. The necessity of adrenalectomy at the time of radical nephrectomy: a systematic review. J Urol 2009;181:20092017.

    • Search Google Scholar
    • Export Citation
  • 13

    Hollingsworth JM, Miller DC, Dunn RL. Surgical management of low-stage renal cell carcinoma: Technology does not supersede biology. Urology 2006;67:11751180.

    • Search Google Scholar
    • Export Citation
  • 14

    Leibovich BC, Blute ML, Cheville JC. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004;171:10661070.

    • Search Google Scholar
    • Export Citation
  • 15

    Shuch B, Lam JS, Belldegrun AS. Open partial nephrectomy for the treatment of renal cell carcinoma. Curr Urol Rep 2006;7:3138.

  • 16

    Chen DY, Uzzo RG. Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. J Natl Compr Canc Netw 2009;7:635642; quiz 643.

    • Search Google Scholar
    • Export Citation
  • 17

    Dash A, Vickers AJ, Schachter LR. Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm. BJU Int 2006;97:939945.

    • Search Google Scholar
    • Export Citation
  • 18

    Lau WK, Blute ML, Weaver AL. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc 2000;75:12361242.

    • Search Google Scholar
    • Export Citation
  • 19

    Lee CT, Katz J, Shi W. Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol 2000;163:730736.

  • 20

    Huang WC, Levey AS, Serio AM. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006;7:735740.

    • Search Google Scholar
    • Export Citation
  • 21

    Go AS, Chertow GM, Fan D. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:12961305.

    • Search Google Scholar
    • Export Citation
  • 22

    Weight CJ, Lieser G, Larson BT. Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticipated benign renal tumours. Eur Urol 2010;58:293298.

    • Search Google Scholar
    • Export Citation
  • 23

    Weight CJ, Larson BT, Gao T. Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival. Urology 2010;76:631637.

    • Search Google Scholar
    • Export Citation
  • 24

    Funahashi Y, Hattori R, Yamamoto T. Ischemic renal damage after nephron-sparing surgery in patients with normal contralateral kidney. Eur Urol 2009;55:209215.

    • Search Google Scholar
    • Export Citation
  • 25

    Rais-Bahrami S, Guzzo TJ, Jarrett TW. Incidentally discovered renal masses: oncological and perioperative outcomes in patients with delayed surgical intervention. BJU Int 2009;103:13551358.

    • Search Google Scholar
    • Export Citation
  • 26

    Campbell SC, Novick AC, Belldegrun A. Guideline for management of the clinical T1 renal mass. J Urol 2009;182:12711279.

  • 27

    Kunkle DA, Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer 2008;113:26712680.

  • 28

    Clark JI, Atkins MB, Urba WJ. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003;21:31333140.

    • Search Google Scholar
    • Export Citation
  • 29

    Messing EM, Manola J, Wilding G. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003;21:12141222.

    • Search Google Scholar
    • Export Citation
  • 30

    Trump D, Elson P, Propert K. Randomized, controlled trial of adjuvant therapy with lymphoblastoid interferon (L IFN) in resected, high risk renal cell carcinoma (HR-RCC) [abstract]. Proc Am Soc Clin Oncol 1996;15:Abstract 648.

    • Search Google Scholar
    • Export Citation
  • 31

    Lam JS, Shvarts O, Leppert JT. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 2005;174:466472; discussion 472; quiz 801.

    • Search Google Scholar
    • Export Citation
  • 32

    Fossa SD, Kjolseth I, Lund G. Radiotherapy of metastases from renal cancer. Eur Urol 1982;8:340342.

  • 33

    Flanigan RC, Mickisch G, Sylvester R. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:10711076.

    • Search Google Scholar
    • Export Citation
  • 34

    Flanigan RC, Salmon SE, Blumenstein BA. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:16551659.

    • Search Google Scholar
    • Export Citation
  • 35

    Mickisch GH, Garin A, van Poppel H. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966970.

    • Search Google Scholar
    • Export Citation
  • 36

    Polcari AJ, Gorbonos A, Milner JE, Flanigan RC. The role of cytoreductive nephrectomy in the era of molecular targeted therapy. Int J Urol 2009;16:227233.

    • Search Google Scholar
    • Export Citation
  • 37

    Culp SH, Tannir NM, Abel EJ. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 2010;116:33783388.

    • Search Google Scholar
    • Export Citation
  • 38

    Leibovich BC, Han KR, Bui MH. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;98:25662575.

    • Search Google Scholar
    • Export Citation
  • 39

    Rosenberg SA, Mule JJ, Spiess PJ. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985;161:11691188.

    • Search Google Scholar
    • Export Citation
  • 40

    Dutcher JP, Fisher RI, Weiss G. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 1997;3:157162.

    • Search Google Scholar
    • Export Citation
  • 41

    Negrier S, Escudier B, Lasset C. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med 1998;338:12721278.

    • Search Google Scholar
    • Export Citation
  • 42

    Fyfe G, Fisher RI, Rosenberg SA. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688696.

    • Search Google Scholar
    • Export Citation
  • 43

    McDermott DF, Regan MM, Clark JI. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133141.

    • Search Google Scholar
    • Export Citation
  • 44

    Motzer RJ, Hutson TE, Tomczak P. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:35843590.

    • Search Google Scholar
    • Export Citation
  • 45

    Yang JC, Sherry RM, Steinberg SM. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:31273132.

    • Search Google Scholar
    • Export Citation
  • 46

    Motzer RJ, Bacik J, Murphy BA. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289296.

    • Search Google Scholar
    • Export Citation
  • 47

    Leibovich BC, Blute ML, Cheville JC. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;97:16631671.

    • Search Google Scholar
    • Export Citation
  • 48

    Motzer RJ, Hutson TE, Tomczak P. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115124.

  • 49

    Motzer RJ, Michaelson MD, Redman BG. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:1624.

    • Search Google Scholar
    • Export Citation
  • 50

    Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884896.

  • 51

    Faivre S, Delbaldo C, Vera K. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:2535.

    • Search Google Scholar
    • Export Citation
  • 52

    Gore ME, Szczylik C, Porta C. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009;10:757763.

    • Search Google Scholar
    • Export Citation
  • 53

    Escudier B, Pluzanska A, Koralewski P. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:21032111.

    • Search Google Scholar
    • Export Citation
  • 54

    Rini BI, Choueiri TK, Elson P. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer 2008;113:13091314.

  • 55

    Rini BI, Halabi S, Rosenberg JE. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28:21372143.

    • Search Google Scholar
    • Export Citation
  • 56

    Sternberg CN, Davis ID, Mardiak J. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:10611068.

    • Search Google Scholar
    • Export Citation
  • 57

    Hudes G, Carducci M, Tomczak P. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:22712281.

  • 58

    Awada A, Hendlisz A, Gil T. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:18551861.

    • Search Google Scholar
    • Export Citation
  • 59

    Clark JW, Eder JP, Ryan D. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:54725480.

    • Search Google Scholar
    • Export Citation
  • 60

    Moore M, Hirte HW, Siu L. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:16881694.

    • Search Google Scholar
    • Export Citation
  • 61

    Strumberg D, Richly H, Hilger RA. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965972.

    • Search Google Scholar
    • Export Citation
  • 62

    Wilhelm SM, Carter C, Tang L. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:70997109.

    • Search Google Scholar
    • Export Citation
  • 63

    Escudier B, Szczylik C, Hutson TE. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:12801289.

    • Search Google Scholar
    • Export Citation
  • 64

    Motzer RJ, Escudier B, Oudard S. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449456.

    • Search Google Scholar
    • Export Citation
  • 65

    Motzer RJ, Escudier B, Oudard S. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:42564265.

    • Search Google Scholar
    • Export Citation
  • 66

    Escudier B, Eisen T, Stadler WM. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125134.

  • 67

    Eisen T, Bukowski RM, Staehler M. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival [abstract]. J Clin Oncol 2006;24(Suppl 1):Abstract 4524.

    • Search Google Scholar
    • Export Citation
  • 68

    Bukowski RM, Eisen T, Szczylik C. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 5023.

    • Search Google Scholar
    • Export Citation
  • 69

    Motzer RJ, Rini BI, Bukowski RM. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:25162524.

  • 70

    Dudek AZ, Zolnierek J, Dham A. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009;115:6167.

  • 71

    Eichelberg C, Heuer R, Chun FK. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 2008;54:13731378.

    • Search Google Scholar
    • Export Citation
  • 72

    Heuer R, Eichelberg C, Zacharias M, Heinzer H. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib [abstract]. Eur Urol Suppl 2009;8:183. Abstract 251.

    • Search Google Scholar
    • Export Citation
  • 73

    Sablin MP, Bouaita L, Balleyguier C. Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients [abstract]. J Clin Oncol 2007;25:Abstract 5038.

    • Search Google Scholar
    • Export Citation
  • 74

    Sablin MP, Negrier S, Ravaud A. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009;182:2934; discussion 34.

  • 75

    Shepard DR, Rini BI, Garcia JA. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab [abstract]. J Clin Oncol 2008;26:Abstract 5123.

    • Search Google Scholar
    • Export Citation
  • 76

    Zimmermann K, Schmittel A, Steiner U. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009;76:350354.

    • Search Google Scholar
    • Export Citation
  • 77

    Dutcher JP, de Souza P, McDermott D. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009;26:202209.

    • Search Google Scholar
    • Export Citation
  • 78

    Gordon MS, Hussey M, Nagle RB. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol 2009;27:57885793.

    • Search Google Scholar
    • Export Citation
  • 79

    Dutcher JP, Nanus D. Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med Oncol, in press.

  • 80

    Nanus DM, Garino A, Milowsky MI. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004;101:15451551.

    • Search Google Scholar
    • Export Citation
  • 81

    Haas N, Manola J, Pins M. ECOG 8802: phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid features [abstract]. Presented at the ASCO Genitourinary Cancers Symposium 2009; February 26–28, 2009; Orlando, Florida. Abstract 285.

    • Search Google Scholar
    • Export Citation
  • 82

    Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003;98:962969.

    • Search Google Scholar
    • Export Citation
  • 83

    Rosen LS, Gordon D, Tchekmedyian NS. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:26132621.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 1 0 0
Full Text Views 403 285 33
PDF Downloads 75 52 5
EPUB Downloads 0 0 0